BiotechTube

Esomeprazole 40mg + Pantoprazole 40mg + Lansoprazole 30mg

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Gastroesophageal Reflux Disease

Conditions

Gastroesophageal Reflux Disease

Trial Timeline

Oct 1, 2006 → May 1, 2007

NCT ID
NCT00410592

About Esomeprazole 40mg + Pantoprazole 40mg + Lansoprazole 30mg

Esomeprazole 40mg + Pantoprazole 40mg + Lansoprazole 30mg is a approved stage product being developed by AstraZeneca for Gastroesophageal Reflux Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00410592. Target conditions include Gastroesophageal Reflux Disease.

What happened to similar drugs?

17 of 20 similar drugs in Gastroesophageal Reflux Disease were approved

Approved (17) Terminated (2) Active (3)
✅rabeprazole and pantoprazoleEisaiApproved
✅rabeprazole + pantoprazoleEisaiApproved
✅Placebo + CisaprideJohnson & JohnsonApproved
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅EsomeprazoleAstraZenecaApproved
✅EsomeprazoleAstraZenecaApproved
✅EsomeprazoleAstraZenecaApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00410592ApprovedCompleted

Competing Products

20 competing products in Gastroesophageal Reflux Disease

See all competitors
ProductCompanyStageHype Score
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
40
Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXdDaiichi SankyoPhase 1/2
39
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
zolbetuximabAstellas PharmaPre-clinical
30
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
zolbetuximabAstellas PharmaPre-clinical
33
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
35
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
FamotidineAstellas PharmaPhase 2/3
38
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
Gentuximab + PaclitaxelSun PharmaceuticalPhase 1/2
28
E3810 + E3810 + PlaceboEisaiPhase 3
40
Rabeprazole ER + RanitidineEisaiPhase 3
40
E3710 + E3710EisaiPhase 1
29
rabeprazole and pantoprazoleEisaiApproved
43
Rabeprazole 20 mgEisaiPhase 2
35
rabeprazole sodiumEisaiPhase 2
35
RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUMEisaiPhase 3
40
Rabeprazole sodium + EsomeprazoleEisaiPhase 3
40
rabeprazole sodium + PlaceboEisaiPhase 3
40